Spartalizumab (anti-PD-1), 程序性细胞死亡 1 (CD279) 抗体

    应用:
  • Animal Model
  • ELISA
  • Flow Cytometry
  • Functional Assay
功能和特点
  • 宿主种属: 人(Human)
  • 种属反应性: 人(Human), 食蟹猴(Cynomolgus monkey)
  • 亚型: Human IgG4SP
  • 偶联: Unconjugated
有货

库存信息

关闭

库存信息

关闭

库存信息

关闭

库存信息

关闭
货号 (SKU) 包装规格 是否现货 价格 数量
Ab169299-100μg
100μg 现货 Stock Image
Ab169299-1mg
1mg 现货 Stock Image
Ab169299-5mg
5mg 现货 Stock Image
Ab169299-10mg
10mg 期货 Stock Image

基本信息

产品名称 Spartalizumab (anti-PD-1), 程序性细胞死亡 1 (CD279) 抗体
别名 斯帕妥珠单抗(抗-PD-1)
英文别名 hPD-1 | Protein PD-1
规格或纯度 无载体, 重组, ExactAb™, 低内毒素, 无叠氮钠, 已验证, 无动物源, ≥95%(SDS-PAGE&SEC-HPLC), 见COA
宿主种属 人(Human)
特异性 PDCD1
应用 ELISA,Functional Assay,Kinetics (BLI),Kinetics (SPR),Flow Cyt
种属反应性 人(Human),食蟹猴(Cynomolgus monkey)
偶联 Unconjugated
作用类型 拮抗剂
作用机制 程序性细胞死亡 1 (CD279) 抗体

AI解读

产品属性

抗体类型 Primary antibody
克隆类型 重组抗体
Format Whole IgG
亚型 Human IgG4SP
轻链亚型 kappa
SDS-PAGE 28.1 kDa (Light Chain) & 51.7 kDa (Heavy Chain), under reducing conditions; 175.9 kDa, under non-reducing conditions.
纯化方法 Protein A purified
纯度 >95%
来源 CHO supernatant
物理外观 Liquid
储存缓冲液 Supplied as a 0.22 μm filtered solution in 100mM Pro-Ac, 20mM Arg, pH 5.0
防腐剂 No
浓度 见COA
储存温度 -80℃储存,避免反复冻融
运输条件 超低温冰袋运输
稳定性与储存 在 -80℃ 下保存 24 个月。收货后建议分装。避免冷冻/解冻循环。
CAS编号和信息 1935694-88-4
分子类型 抗体

图片

Spartalizumab (anti-PD-1) (Ab169299) - ELISA
Immobilized Recombinant Human PD-1 Protein at 1 μg/mL can bind Spartalizumab (anti-PD-1) (Ab169299) with the EC₅₀ of 39.7 ng/mL.

Spartalizumab (anti-PD-1) (Ab169299) - SEC
The purity of Spartalizumab (anti-PD-1) (Ab169299) is more than 95% verified by HPLC.

Spartalizumab (anti-PD-1) (Ab169299) - ELISA
Immobilized Recombinant Human PD-1 Protein (rp176241) at 1.0 μg/mL can bind Spartalizumab (anti-PD-1) (Ab169299) with the EC50 of 13.27 ng/mL.

关联靶点(人)

PDCD1 Tclin 程序性细胞死亡蛋白 1(Programmed cell death protein 1) (0 活性数据)
活性类型 活性值-log(M) 作用机制 期刊 参考文献(PubMed IDs)
PDCD1 Tclin Programmed cell death protein 1 (14 活性数据)
活性类型 Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID

作用机制

作用机制 Action Type target ID Target Name Target Type Target Organism Binding Site Name 参考文献

技术规格说明书

质检证书(CoA,COO,BSE/TSE 和分析图谱)

C of A & Other Certificates(BSE/TSE, COO):
输入批号以搜索分析图谱:

通过匹配包装上的批号来查找并下载产品的 COA,每批产品都进行了严格的验证,您可放心使用!

找到4个结果

批号(Lot Number) 证书类型 日期 货号
ZJ24F1012891 分析证书 24-10-25 Ab169299
ZJ24F1012890 分析证书 24-10-25 Ab169299
ZJ24F1012889 分析证书 24-10-25 Ab169299
ZJ23F1202018 分析证书 23-12-13 Ab169299

可替换产品

参考文献

1. Kline J, Gajewski TF.  (2010)  Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancer..  Curr Opin Investig Drugs,  11  (12): (1354-9).  [PMID:21154117] [10.1021/op500134e]
2. Hall RD, Gray JE, Chiappori AA.  (2013)  Beyond the standard of care: a review of novel immunotherapy trials for the treatment of lung cancer..  Cancer Control,  20  (1): (22-31).  [PMID:23302904] [10.1021/op500134e]
3. Burova E, Hermann A, Waite J, Potocky T, Lai V, Hong S, Liu M, Allbritton O, Woodruff A, Wu Q et al..  (2017)  Characterization of the Anti-PD-1 Antibody REGN2810 and Its Antitumor Activity in Human PD-1 Knock-In Mice..  Mol Cancer Ther,  16  (5): (861-870).  [PMID:28265006] [10.1021/op500134e]
4. L R Finger,J Pu,R Wasserman,R Vibhakar,E Louie,R R Hardy,P D Burrows,L G Billips.  (1997-10-23)  The human PD-1 gene: complete cDNA, genomic organization, and developmentally regulated expression in B cell progenitors..  Gene,  197  ((1-2)): (177-187).  [PMID:9332365]
5. Shinohara, T T, Taniwaki, M M, Ishida, Y Y, Kawaichi, M M and Honjo, T T..  (1994)  Structure and chromosomal localization of the human PD-1 gene (PDCD1)..  Genomics,  [PMID:7851902]
6. Prokunina, Ludmila L and 23 more authors..  (2002)  A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans..  Nature genetics,  [PMID:12402038]
7. Topalian, Suzanne L SL and 29 more authors..  (2012)  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer..  The New England journal of medicine,  (28): [PMID:22658127]
8. Robert, Caroline C and 27 more authors..  (2015)  Nivolumab in previously untreated melanoma without BRAF mutation..  The New England journal of medicine,  (22): [PMID:25399552]
9. McDermott, J J and Jimeno, A A..  (2015)  Pembrolizumab: PD-1 inhibition as a therapeutic strategy in cancer..  Drugs of today (Barcelona, Spain : 1998),  [PMID:25685857]
10. Na, Zhenkun and 6 more authors..  (2017)  Structural basis for blocking PD-1-mediated immune suppression by therapeutic antibody pembrolizumab..  Cell research,  [PMID:27325296]
11. Pascolutti, Roberta R and 6 more authors..  (2016)  Structure and Dynamics of PD-L1 and an Ultra-High-Affinity PD-1 Receptor Mutant..  Structure (London, England : 1993),  (4): [PMID:27618663]
12. Horita, Shoichiro S and 5 more authors..  (2016)  High-resolution crystal structure of the therapeutic antibody pembrolizumab bound to the human PD-1..  Scientific reports,  (13): [PMID:27734966]
13. Tan, Shuguang S and 15 more authors..  (2017)  An unexpected N-terminal loop in PD-1 dominates binding by nivolumab..  Nature communications,  (6): [PMID:28165004]
14. Berger, Kristin Nicole KN and Pu, Jeffrey Jiayu JJ..  (2018)  PD-1 pathway and its clinical application: A 20year journey after discovery of the complete human PD-1 gene..  Gene,  (5): [PMID:28951311]

溶液计算器